Imaging of Brain Receptors Using (11C)mGlu1

Stopped early · Phase 1

Conditions studied: Dosimetry, Pharmacokinetics

In brief

Background: \- (11C)mGlu1 is a new drug that helps to show where a protein, mGluR1, is found in the brain. The drug contains a small amount of radioactivity that can be detected by imaging studies like positron emission tomography (PET) scans. By looking at the mGluR1 receptors, researchers hope to better understand how they are involved in general health, brain disorders, and addiction. Objectives: * To test how (11C)mGlu1 is distributed in the brain and body. * To measure how mGluR1 receptors display (11C)mGlu1 during imaging studies. Eligibility: \- Healthy volunteers between 18 and 50 years of age. Design: * Participants will be screened with a medical history, physical exam, and blood and urine tests. This study requires four visits to the NIH Clinical Center. * Participants will have an initial evaluation, a magnetic resonance imaging (MRI) scan, a PET scan, and a final blood sample after the PET scan, all at different visits. * The MRI and PET scans will focus on the brain. Participants will receive (11C)mGlu1, and have scans to see how it shows up in the brain. * Some participants will have whole body imaging studies to see how (11C)mGlu1 shows up in the body.

Key facts

Study ID
NCT01420952
Run by
National Institute of Mental Health (NIMH)
People needed
3
Starts
2011-07-29
Expected to finish
2012-11-27
Last updated by the study team
2019-12-16

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.